Machine Learning Models for Predicting Smoking-Related Health Decline and Disease Risk

Vaskar Chakma *, MD Jaheid Hasan Nerab †, Abdur Rouf †, Abu Sayed, Hossem MD Saim, Md. Nournabi Khan · 2025

Read Machine Learning Models for Predicting Smoking-Related Health Decline and Disease Risk by Vaskar Chakma *, MD Jaheid Hasan Nerab †, Abdur Rouf †, Abu Sayed, Hossem MD Saim, Md. Nournabi Khan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2511-14682.txt.

Introduction

Vaskar Chakma, MD Jaheid Hasan Nerab, and four co-authors test whether machine learning can flag smoking-related health decline early. Smoking harms the heart, liver, kidneys, and metabolism, yet routine screening often misses the first warning signs. The team compares three prediction methods on health screening records from more than fifty-five thousand people.

The study weighs Random Forest, XGBoost, and LightGBM models using body measures, blood tests, and personal background data. The authors stress clear, explainable results that clinics could actually use, rather than chasing a novel algorithm. Their comparison shows which approach best picks out people at high risk, which could help doctors act before late-stage disease sets in.

Catalog record

CREATORVaskar Chakma *, MD Jaheid Hasan Nerab †, Abdur Rouf †, Abu Sayed, Hossem MD Saim, Md. Nournabi Khan
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE92 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2511-14682

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Machine Learning Models for Predicting Smoking-Related Health Decline and Disease Risk Thanks: These are corresponding authors. † These authors contributed equally. Vaskar Chakma *, MD Jaheid Hasan Nerab †, Abdur Rouf †, Abu Sayed, Hossem MD Saim, Md. Nournabi Khan Abstract Smoking continues to be a major preventable cause of death worldwide, affecting millions through damage to the heart, metabolism, liver, and kidneys. However, current medical screening methods often miss the early warning signs of smoking-related health problems, leading to late-stage diagnoses when treatment options become limited. This study presents a systematic comparative evaluation of machine learning approaches for smoking-related health risk assessment, emphasizing clinical interpretability and practical deployment over algorithmic innovation. We analyzed health screening data from 55,691 individuals, examining various health indicators, including body measurements, blood tests, and demographic information. We tested three advanced prediction algorithms - Random Forest, XGBoost, and LightGBM - to determine which could most accurately identify people at high risk. This study employed a cross-sectional design to classify current smoking status based on health screening biomarkers, not to predict future disease development. Our Random Forest model performed best, achieving an Area Under the Curve (AUC) of 0.926, meaning it could reliably distinguish between high-risk and lower-risk individuals. Using SHAP (SHapley Additive exPlanations) analysis to understand what the model was detecting, we found that key health markers played crucial roles in prediction: blood pressure levels, triglyceride concentrations, liver enzyme readings, and kidney function indicators (serum creatinine) were the strongest signals of declining health in smokers. These results demonstrate that artificial intelligence can serve as a powerful tool for early disease detection in smokers. By identifying at-risk individuals before conventional symptoms appear, healthcare providers could intervene earlier with personalized prevention strategies. Implementing these predictive systems in public health programs could reduce the enormous burden smoking places on healthcare systems while shifting medical care from reactive treatment to proactive prevention. K eywords Smoking-Related Diseases \cdot Machine Learning Prediction Models \cdot Health Risk Assessment \cdot Predictive Analytics in Healthcare \cdot Early Disease Detection \cdot Public Health Informatics \cdot Artificial Intelligence in Medicine 1 Introduction Smoking remains one of the most pressing global public health challenges, representing a complex interplay of addiction, behavioral patterns, and progressive biological damage [ 1 ] . Each year, tobacco use is responsible for over 8 million deaths worldwide, with the World Health Organization estimating that nearly half of all smokers will ultimately succumb to smoking-related illnesses [ 2 , 3 ] . While lung cancer and chronic obstructive pulmonary disease (COPD) are the most widely recognized consequences, smoking also drives cardiovascular disease, metabolic dysfunction, and systemic inflammation that can compromise virtually every organ system [ 4 , 5 ] . Perhaps most concerning is that this damage frequently progresses insidiously over years, often becoming irreversible before clinical symptoms manifest [ 6 ] . Despite decades of comprehensive public health initiatives and overwhelming scientific evidence, approximately 1.3 billion people worldwide continue to use tobacco products [ 7 ] . Many smokers harbor what might be termed "optimistic bias," believing they can quit before substantial harm occurs or that they will somehow avoid the worst outcomes. The non-linear trajectory of smoking-related decline—characterized by years of subclinical damage that suddenly manifests as severe disease—highlights critical limitations in reactive diagnostic approaches that await obvious symptoms before intervention. These delays result in lost opportunities for prevention and early therapeutic intervention. Our research aims to transform this reactive paradigm by developing advanced predictive tools that can detect risk at substantially earlier stages [ 8 , 9 ] . We hypothesize that smoking leaves distinct, systemic biological signatures across cardiovascular, metabolic, hepatic, and oral health pathways that machine learning algorithms can identify long before conventional clinical thresholds are exceeded [ 10 , 2 ] . By simultaneously analyzing these diverse biomarkers, we aim to construct a more comprehensive and clinically relevant assessment of smoking-related health decline. This holistic approach addresses significant gaps in prior research, which has often concentrated on single disease endpoints or limited feature sets, thereby constraining real-world applicability [ 11 , 12 , 13 ] . A critical innovation in our study is the direct comparison of machine learning models with established clinical risk assessment tools, including the Framingham cardiovascular risk score. This benchmarking exercise tests whether advanced algorithms provide measurable advantages over standard, widely validated approaches—a crucial step for building confidence among clinicians and policymakers who will ultimately implement these systems in practice. A fundamental principle guiding our work is model interpretability. We employ SHAP (SHapley Additive exPlanations) values to elucidate how each variable contributes to individual risk predictions [ 14 , 15 ] . This transparency is essential for fostering clinician trust and facilitating shared decision-making, positioning these tools as decision support rather than replacements for professional judgment. We also address practical considerations for clinical implementation, including integration into existing healthcare workflows, appropriate clinical responses to risk alerts, and responsible management of false positive and false negative predictions to minimize potential harm. Understanding these operational aspects is critical for successful translation from research to practice. Our study places particular emphasis on algorithmic fairness by thoroughly characterizing the geographic, ethnic, and socioeconomic distribution of our study population. We explicitly analyze how data quality issues—such as extreme laboratory value outliers—might influence model performance and generalizability. This attention to equity ensures that our models are not only technically sound but also ethically responsible and applicable across diverse populations. Through the integration of advanced algorithms, rigorous comparison with traditional assessment tools, realistic evaluation of clinical adoption pathways, and strong emphasis on equity, we aim to advance predictive medicine for smoking-related disease beyond academic exercises toward genuinely impactful, patient-centered applications. By identifying at-risk individuals before irreversible damage occurs, these tools could enable more timely interventions, facilitate targeted prevention strategies, and ultimately improve public health outcomes for millions of people affected by tobacco use. This investigation employs a cross-sectional analytical framework wherein all predictor variables (demographic characteristics, anthropometric measurements, and biochemical biomarkers) and the outcome variable (current smoking status) were collected simultaneously during a single health screening visit. The prediction task is therefore classification -identifying individuals who are current smokers based on their present physiological state, rather than prognosis , which would entail predicting future disease onset or health decline over time. No longitudinal follow-up data were available; thus, temporal causality cannot be inferred from our results. The clinical utility of this approach lies in leveraging routinely collected health screening data to detect physiological signatures of smoking exposure that may indicate early-stage damage before overt clinical symptoms manifest, thereby enabling timely intervention and smoking cessation support. Our contribution lies not in novel algorithm development, but in rigorous comparative evaluation of established machine learning methods applied to comprehensive multi-system health screening data, with particular emphasis on clinical interpretability through SHAP analysis, validation against traditional risk scores (Framingham), and practical considerations for real-world deployment. This systematic approach addresses critical gaps in prior smoking risk prediction research, which often focuses on single disease endpoints or lacks adequate attention to explainability—essential prerequisites for clinical adoption. 2 Related Study The prediction and assessment of smoking-related health risks has garnered substantial research attention over the past decades, with increasing momentum following the integration of machine learning methodologies

Read the complete text